Eagle Pharmaceuticals, Inc.(EGRX)

Description: Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.

---

Keywords: Medicine Pharmaceutical Lymphoma Lung Cancer Organic Chemistry Stroke Small Cell Lung Cancer Toxicology Chronic Lymphocytic Leukemia Heparin Angioplasty Lymphocytic Leukemia Thrombocytopenia Organochlorides Percutaneous Treatment Of Chronic Lymphocytic Leukemia Argatroban Benzimidazoles Injectable Products Pemetrexed Percutaneous Transluminal Angioplasty Bivalirudin Heparin Induced Thrombocytopenia Nitrogen Mustards

---

Home Page: www.eagleus.com

EGRX Technical Analysis

50 Tice Boulevard
Woodcliff Lake, NJ 07677
United States
Phone: 201 326 5300

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)